Professor Andrew Wardley

Professor Andrew Wardley is an internationally-renowned consultant medical oncologist and breast cancer specialist with practice across the UK with Sciensus (Healthcare at Home), who specialises in the diagnosis, treatment and integrated care of breast cancer. His expertise in breast cancer research, innovation and transformation has enabled him to ensure that the multiple international clinical trials he has led throughout his career, have been adopted in clinical practice to improve the outcomes and the experience of people with breast cancer. Professor Wardley currently sees patients at Cromwell Hospital, Cancer Services Limited, and various GenesisCare locations. He has extensive experience using system leadership for service innovation.

Professor Wardley believes in research-driving care; ‘a question to answer for every person’. He conceived, developed and led a fully-integrated, patient-focused, research-centred, holistic breast cancer service that directly improves patient care and access to novel treatments. This integrated cancer care system, introduced in Greater Manchester in 2001, has been adopted by NHS England and the European Code of Cancer Practice. In 2020, Professor Wardley founded Outreach Research and Innovation Group to continue developing this model further.

Professor Wardley was a major driver to developing cancer research and services in Greater Manchester and Cheshire, creating collaborative partnerships with international research groups and pharma. He co-founded Manchester Breast Centre and helped to design and develop Manchester Cancer Research Centre, Manchester Academic Health Science Centre and Greater Manchester Cancer. His collaborative approach was also instrumental in forming NIHR Manchester Clinical Research Facility, a key factor in a successful NIHR Biomedical Research Centre bid and CRUK Major Centre and Manchester Academic Health Science Centre funding.

Professor Wardley has educated two generations of medical oncologists and breast cancer specialists through education schemes from the European Society of Medical Oncology, the European School of Oncology, the Association of Cancer Physicians and the Royal College of Physicians. He is an active member of various international trial co-operatives.